Evolution of the mir-155 family and possible targets in cancers and the immune system

Guang-Bing Xie1, Wei-Jia Liu, Zhi-Jun Pan

  • 1College of Orient Science and Technology, Hunan Agriculture University, Changsha, China

Insights

The microRNA-155 (miR-155) family evolved independently, with lineage-specific gains and alternative splicing driving its evolution. This family plays a conserved role in cancer and immunity, targeting genes like CCND1 and EGFR.

Area of Science:

  • Evolutionary biology
  • Molecular biology
  • Genetics

Background:

  • The microRNA-155 (miR-155) family is implicated in various cancers and immune system regulation.
  • The evolutionary trajectory and mechanisms of the miR-155 family remain incompletely understood.

Purpose of the Study:

  • To elucidate the evolutionary history of the miR-155 family.
  • To analyze the functional roles of miR-155 in cancer and immunity.

Main Methods:

  • Comparative genomic analysis to trace miRNA evolution.
  • Identification of lineage-specific miRNA gains and arm switching events.
  • High-throughput methods including Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis.

Main Results:

  • miR-155 evolved independently with lineage-specific miRNA gains.
  • Alternative splicing contributes to the evolution of intragenic miRNAs within the miR-155 family.
  • CCND1 and EGFR identified as significantly enriched target genes potentially linked to cancer.
  • cebpb, VCAM1, and SMAD2 highlighted as vital in miR-155-regulated immune responses.

Conclusions:

  • The miR-155 family is evolutionarily conserved.
  • CCND1 and EGFR are potential miR-155 targets in cancer progression.
  • cebpb, VCAM1, and SMAD2 are key factors in miR-155-mediated immune activities.

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
20.7K
MicroRNAs01:22

MicroRNAs

9.7K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.6K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

3.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
6.9K